FDA Releases Draft Guidance on Collecting Race and Ethnicity Data in Clinical Trials

Summary

The Food and Drug Administration (FDA) has made available a draft guidance for industry on collecting standardized race and ethnicity data in clinical trials for FDA-regulated products, developed in collaboration with the Office of Management and Budget (OMB)